Cytoprotective and supportive care agents:

Indications for: ZINECARD

To reduce the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300mg/m2 and will continue to receive doxorubicin therapy to maintain tumor control.

Adult Dosage:

Give by slow IV push or rapid drip IV infusion. Doxorubicin should be administered within 30 minutes after starting Zinecard infusion. Administer in 10:1 ratio (eg, 500mg/m2 Zinecard: 50mg/m2 doxorubicin). Renal impairment (CrCl <40mL/min): reduce ratio to 5:1 (eg, 250mg/m2 Zinecard: 50mg/m2 doxorubicin). Hepatic impairment: may need to reduce doxorubicin dose, therefore Zinecard dose must be reduced (maintaining 10:1 ratio).

Children Dosage:

Not recommended.

ZINECARD Contraindications:

Chemotherapy regimens that do not contain an anthracycline.

ZINECARD Warnings/Precautions:

Not recommended for use with initiation of doxorubicin. Renal or hepatic impairment. Monitor cardiac function and for myelosuppression; obtain CBCs frequently. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.

ZINECARD Classification:

Chelating agent.

Adverse Reactions:

Inj site pain, myelosuppression, possible secondary malignancies (see literature).

Drug Elimination:


Generic Drug Availability:


How Supplied:

Single-use vial—1 (w. diluent)